1. World Health Organization. Obesity: preventing and managing the global epidemic. 1997, Geneva: WHO. 2. Biddle S, García Bengoechea E, Pedisic Z, et al. Screen Time, Other Sedentary Behaviours, and Obesity Risk in Adults: A Review of Reviews. Curr Obes Rep. 2017; 6(2):134-147. 3. Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016; 45(4): 571-579. 4. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3): 254-266. 5. Yeo G., Heisler L. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci. 2012; 15 (10): 1343–1349. 6. Lam D., Garfield A., Marston O. et al. Brain serotonin system in the coordination of food intake and body weight. Pharmacol Biochem Behav. 2010; 97 (1): 84–91. 7. Campbell E, Franks A, Joseph P. Adolescent obesity in the past decade: A systematic review of genetics and determinants of food choice. J Am Assoc Nurse Pract. 2019; 31(6): 344-351. 8. Zhi C, Huang J, Wang J, et al. Connection between gut microbiome and the development of obesity. Eur J Clin Microbiol Infect Dis. 2019; Jul 31. doi: 10.1007/s10096-019-03623-x. 9. Kadowaki T, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116: 1784-1792. 10. Bastard J, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006 Mar;17(1):4-12. 11. Montanari T, Pošćić N, Colitti M. Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review. Obes Rev. 2017; 18(5):495-513. 12. Fernández-Verdejo R, Marlatt K, Ravussin E, Galgani J. Contribution of brown adipose tissue to human energy metabolism. Mol Aspects Med. 2019 Jul 16. pii: S0098-2997(19)30029-9. doi: 10.1016/j.mam.2019.07.003 13. Must A., Spadano J., Coakley E. et al. The disease burden associated with overweight and obesity. JAMA 1999, 282, 1523-1529. 14. Guh D., Zhang W., Bansback N. et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88. 15. Lenz M., Richter T., Muhlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Arztebl Int 2009; 106: 641-648. 16. Alberti K, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005; 366: 1059-62. 17. (WHO (2020), Obesity and overweight, https://www.who.int/news-room/factsheets/detail/obesity-and-overweight). 18. Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008 Sep;32(9):1431-7. 19. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-112 20. https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=14933 21. OECD (2021), Overweight or obese population (indicator). doi:10.1787/86583552-en (Accessed on 28 August 2021) 22. Баланова Ю. А., Шальнова С. А., Деев А. Д. и др. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-30. doi:10.15829/1560- 4071-2018-6-123-130). 23. Ожирение: этиология, патогенез, клинические аспекты. Под редакцией И.И. Дедова, Г.А. Мельниченко. Москва, Медицинское информационное агентство, 2004 г: 16-21. 36 24. Garvey W, Garber A, Mechanick J, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocr Pract. 2014; 20: 977-989. 25. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneva, World Health Organization, 1995 (Technical Report Series, No. 854):329. 26. Kuczmarski RJ et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991.Journal of the American Medical Association, 1994, 272:205-211. 27. Swinburn BA et al. Body composition differences between Polynesians and Caucasians assessed by bioelectrical impedance. International Journal of Obesity and Related Metabolic Disorders, 1996, 20:889-894. 28. Forbes GB, Reina JC. Adult lean body mass decline with age: some longitudinal observations. Metabolism: Clinical and Experimental, 1970, 19:653-663. 29. Rolland-Cachera MF et al. Body mass index variations - centiles from birth to 87 years. European Journal of Clinical Nutrition, 1991, 45:13-21. 30. Ross R et al. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships. American Journal of Clinical Nutrition, 1994, 59:1277- 1285. 31. Norgan NG, Jones PRM. The effect of standardizing the body mass index for relative sitting height. International Journal of Obesity and Related Metabolic Disorders, 1995, 19:206-208. 32. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. British Medical Journal, 1995, 311:158-161. 33. Han TS et al. Waist circumference relates to intra-abdominal fat mass better than waist:hip ratio in women. Proceedings of the Nutrition Society, 1995, 54:152A. 34. Pouliot MC et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. American Journal of Cardiology, 1994, 73:460-468. 35. Ross R et al. Quantification of adipose tissue by MRI: relationship with anthropometric variables. Journal of Applied Physiology, 1992, 72:787-795. 36. Lean MEJ, Han TS, Deurenberg P. Predicting body composition by densitometry from simple anthropometric measurements. American Journal of Clinical Nutrition, 1996, 63:4-14. 37. Han TS et al. Waist circumference reduction and cardiovascular benefits during weight loss in women. International Journal of Obesity and Related Metabolic Disorders, 1997, 21: 127-134. 38. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in bodymass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 377(9765): 557-567. 39. Wormser D, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011; 377(9771):1085–95. 40. Mancia G, De Backer G, Dominiczak A, Cifkova R, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007 25(9):1751-62. doi: 10.1097/HJH.0b013e3282f0580f. 41. Masa J, et al. Obesity hypoventilation syndrome. Eur Respir Rev. 2019 Mar 14; 28(151). pii: 180097. 42. Macavei V, et al. Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing. J Clin Sleep Med 2013; 9: 879–884. 43. Camilleri M, et al. Gastrointestinal Complications of Obesity. Gastroenterology. 2017 May; 152(7):1656-1670. 44. Khatua B, et al. Obesity and pancreatitis. Curr Opin Gastroenterol. 2017 Sep;33(5):374-382. 37 45. Escobar-Morreale H, et al. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and metaanalysis. Hum Reprod Update. 2017 Jul 1;23(4):390-408. 46. Daniel E, Newell-Price J. Cushing's syndrome. Medicine, Volume 45, Issue 8, 2017, pp. 475- 479. 47. Stuart C, et al. Acanthosis nigricans. J Basic Clin Physiol Pharmacol. 1998; 9(2-4):407-18. 48. Rohde K, et al. Genetics and epigenetics in obesity. Metabolism. 2019 Mar; 92: 37-50. 49. Mirzababaei A, et al. Risk of hypertension among different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies. J Hum Hypertens. 2019 May; 33(5): 365-377. 50. Deng G, et al. Associations of anthropometric adiposity indexes with hypertension risk: A systematic review and meta-analysis including PURE-China. Medicine (Baltimore). 2018 Nov; 97(48):e13262. 51. Biondi B. Thyroid and obesity: an intriguing relationship. Journal of Clinical Endocrinology and Metabolism. 2010; 95: 3614–3617. 52. Rotondi M, et al. Thyroid and obesity: not a one-way interaction. Journal of Clinical Endocrinology and Metabolism. 2011; 96: 344–346. 53. Laurberg P, et al. Thyroid function and obesity. European Thyroid Journal. 2012; 1: 159–167. 54. Pearce E. Thyroid hormone and obesity. Current Opinion in Endocrinology Diabetes and Obesity. 2012; 19: 408–413. 55. Duntas L, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013; 23: 646–653. 56. Boscaro M, Arnaldi G. Approach to the patient with possible Cushing's syndrome. J Clin Endocrinol Metab. 2009; 94(9): 3121-31. 57. Auriemma R. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018; 13(2): 99-106. 58. Santos-Silva C, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity. 2011; 19: 800–805. 59. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of WHO/IDF Consultation. 2006. 60. Tang Z. et al. Sex, Age, and BMI Modulate the Association of Physical Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases Observed at Shuguang Hospital, China //BioMed research international. – 2019. – Т. 2019. 61. Pereira-Santos M, et al. Obesity and vitamin D deficiency: a systematic review and metaanalysis. Obes Rev. 2015; 16(4): 341-349. 62. Lotito A, et al. Serum Parathyroid Hormone Responses to Vitamin D Supplementation in Overweight/Obese Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients. 2017; 9(3): pii: E241. 63. Hjelmesæth J. et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study //Cardiovascular diabetology. – 2009. – Т. 8. – №. 1. – С. 7. 64. Soares M. J. et al. Vitamin D and parathyroid hormone in insulin resistance of abdominal obesity: cause or effect? //European journal of clinical nutrition. – 2011. – Т. 65. – №. 12. – С. 1348-1352. 65. Silidker M. S. et al. Ultrasound evaluation of cholelithiasis in the morbidly obese //Gastrointestinal radiology. – 1988. – Т. 13. – №. 1. – С. 345-346. 66. de Moura Almeida A. et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound //World journal of gastroenterology: WJG. – 2008. – Т. 14. – №. 9. – С. 1415. 38 67. Kapur V, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017; 13(3): 479-504. 68. Bozkurt B, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016; 134(23): e535- e578. 69. Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129-2200. 70. Jensen M, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014; 63(25 Pt B): 2985-3023. 71. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient—2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring), 2013; 21(0 1): S1–27. doi:10.1002/oby.20461. 72. Stoker D. Management of the bariatric surgery patient. Endocrinol Meatb Clin North Am 2003; 32: 437-457 73. Herpertz S, Kielmann R, Wolf A. et al. Do psychosocial variables predict weight loss or mental health after obesity surgery? A systematic review. Obes Res 2004;12:1554-69 74. Kalarchian M., Marcus M., Levine M. et al. Relationship of psychiatric disorders to 6-month outcomes after gastric bypass. Surg Obes Relat Dis 2008; 4: 544-9 75. Tindle H., Omalu B., Courcoulas A. et al. Risk of suicide after long-term follow-up from bariatric surgery. Am J Med. 2010; 123: 1036-42. 76. Sarwer D., Cohn N., Gibbons L. et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg 2004; 14: 1148-56. 77. Van Hout G., Verschure S., Van Heck G. Psychosocial predictors of success following bariatric surgery. Obes Surg 2005; 15(4): 552-60 78. Wadden T., Sarwer D. Behavioral Assessment of Candidates for Bariatric Surgery: A PatientOriented Approach. Obesity 2006; 14 (Suppl): 53S - 62S 79. Geerts W., Pineo G., Heit J. et al. Prevention of venous thromboembolism: the seventh ACCP conference of antithrombotic and thrombolytic therapy. Chest 2004; 126 (3 Suppl): 338S-400S 80. Martin L., Finigan K., Nolan T. Pregnancy after adjustable gastric banding. Obstetr Gynecol 2000; 95(6, pt 1): 927-930 81. Gerrits E., Ceulemans R., van hee R. et al. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg 2001; 11: 303-306 82. Yang C., Lee W., Wang H. et al. The influence of Helicobacter pylori infection on the development of gastric ulcer in symptomatic patients after bariatric surgery. Obes Surg 2006; 16: 735-739 83. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403. 84. Blundell JE, Dulloo AG, Salvador J, et al. on behalf of the EASO SAB Working Group on BMI: Beyond BMI – phenotyping the obesities. Obes Facts 2014; 7: 322–328. 85. Schwarz PE, Lindström J, Kissimova-Scarbeck K, et al. The European perspective of type 2 diabetes prevention: diabetes in Europe – prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes 2008; 116: 167–172. 39 86. Hainer V, Toplak H, Mitrakou A: Treatment modalities of obesity: What fits whom? Diabetes Care 2008; 31(suppl 2):S269–S277. 87. Sampsel S, May J: Assessment and management of obesity and comorbid conditions. Dis Manag 2007; 1: 252–265. 88. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129(suppl 2): S102–S138. 89. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation (WHO Technical Report Series 894). Geneva, WHO, 1998. www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/ (last accessed November 30, 2015). 90. Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a Diabetes Care editors’ expert forum. Diabetes Care. 2015;38(8):1567-1582. 91. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract, 2016; 22(Suppl 3). 92. Shai I, Schwarzfuchs D, Henkin Y, et al, for the Dietary Intervention Randomized Controlled Trial (DIRECT) Group: Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008; 359:229–241. 93. Dernini S, Berry EM: Mediterranean diet: from a healthy diet to a sustainable dietary pattern. Front Nutr 2015;2: 1–6. 94. Estruch R, Ros E, Salas-Salvadó J, et al for the PREDIMED Study Investigators: Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279– 1290. 95. Avenell A., Brown T., McGee M. et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet 2004; 17: 317- 35. 96. Dansinger M.L., Gleason J.A., Griffith J.L. et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk ReductionA Randomized Trial. JAMA. 2005;293(1):43-53. doi:10.1001/jama.293.1.43. 97. Sharma M: Behavioural interventions for preventing and treating obesity in adults. Obes Rev 2007; 8: 441–449 98. Lang A, Froelicher ES: Management of overweight and obesity in adults: behavioral intervention for long-term weight loss and maintenance. Eur J Cardiovasc Nurs 2006; 5: 102– 114. 99. Moffitt R, Haynes A, Mohr P: Treatment beliefs and preferences for psychological therapies for weight management. J Clin Psychol 2015; 71: 584–596. 100. Willis LH, Slentz CA, Bateman LA, Shields AT, Piner LW, Bales CW, Houmard JA, Kraus WE: Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol 2012; 113:1831–1837. 101. Geliebter A, Christopher N, Ochner CN, Dambkowski CL, Hashim SA: Obesity-related hormones and metabolic risk factors: a randomized trial of diet plus either strength or aerobic training versus diet alone in overweight participants. J Diabetes Obes 2015; 1: 1–7. 102. Poirier P, Després JP: Exercise in weight management of obesity. Cardiol Clin 2001; 19: 459–470. 103.Chin S.-H., Kahathuduwa C. N., Binks M. Physical activity and obesity: what we know and what we need to know. Obesity Reviews. 17 (2016): 1226-1244. 40 104.Stephens S.K., Cobiac L.J., Lennert Veerman. J. Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Preventive Medicine 62 (2014): 167–178. 105.Malone M. Medications associated with weight gain //Annals of Pharmacotherapy. – 2005. – Т. 39. – №. 12. – С. 2046-2055. 106.American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract, 2016; 22(Suppl 3)] [ADA Diabetes Care 2017;40(Suppl 1): S44-S47. 107.Rucker D., Padwal R., Li S. et al. Long term pharmacotherapy for obesity and overweight updated meta-analysis. British Medical Journal 2007; 335: 1194-1199. 108.Avenell A., Broom J., Brown T. et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii-iv, 1-182. 109.Bray GA: Medical treatment of obesity: the past, the present and the future. Best Pract Res Clin Gastroenterol 2014; 28:665-684. 110.Pucci A, Finer N: New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol 2015; 31:142-152. 111.Torgerson JS, Hauptman J, Boldrin MN, SjoћИstroћИm L: Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155-161. 112.Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, ZuћБnћГigaGuajardo S, Van Gaal L: X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005; 7:699-708. 113.Williamson D., Pamuk E., Thun M. et al. Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol 1999; 149: 491-503. 114.W.P.T. Jzmes Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119–25. 115.Dedov et al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts 2018; 11:335–343. 116.Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера». Ожирение и метаболизм. 2016; 1:36-44. 117.Sari R. et al. Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women //Clinical and experimental medicine. – 2010. – Т. 10. – №. 3. – С. 179-184. 118.Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med.2015;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892. 119.le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017; 389(10077):1399-1409. doi:10.1016/s0140-6736(17)30069- 7. 120.Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. doi:10.1038/ij o.2016.52 121. Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity (2013) 37, 1443-1451; doi:10.1038/ijo.2013.120 122.Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4):311-22. DOI: 10.1056/NEJMoa1603827 41 123.TA Wadden, P Hollander, S Klein et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity (2013) 37, 1443-1451; doi:10.1038/ijo.2013.120]. 124.P-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med.2015;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892]. 125.Lenz M, Richter T, Muhlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Arztebl Int. 2009;106(40):641-648. doi: 10.3238/arztebl.2009.0641. 126.Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery A Systematic Review and MetaAnalysis. JAMA. 2004;292(14):1724. doi: 10.1001/jama.292.14.1724. 127.Fried M, Yumuk V, Oppert J-M, et al. Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery. Obesity Facts. 2013;6(5):449-468. doi: 10.1159/000355480. 128.Guidelines for Laparoscopic and Open Surgical Treatment of Morbid Obesity. Obes. Surg. 2000;10(4):378-379. doi: 10.1381/096089200321629184. 129.American College of Endocrinology (ACE), American Association of Clinical Endocrinologists (AACE): AACE/ACE position statement on the prevention, diagnosis and treatment of obesity. Jacksonville, American Association of Clinical Endocrinologists, 1998. 130.Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. The American Journal of Medicine. 2009;122(3):248- 256.e245. doi: 10.1016/j.amjmed.2008.09.041. 131.Apovian CM, Baker C, Ludwig DS, Hoppin AG, Hsu C, Lenders C, et al: Best practice guidelines in pediatric/adolescent weight loss surgery. Obes Res 2005;13:274–282. 132.Inge TH, Krebs NF, Garcia VF, Skelton JA, Guice KS, Strauss RS, et al: Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics 2004;114:217– 223. 133.Sugerman HJ, Sugerman EL, DeMaria EJ, Kellum JM, Kennedy C, Mowery Y, et al: Bariatric surgery for severely obese adolescents. J Gastrointest Surg 2003; 7:102–107. 134.Dolan K, Creighton L, Hopkins G, Fielding G: Laparoscopic gastric banding in morbidly obese adolescents. Obes Surg 2003; 13:101–104. 135.Stanford A, Glascock JM, Eid GM, Kane T, Ford HR, Ikramuddin S, et al: laparoscopic Rouxen-Y gastric bypass in morbidly obese adolescents. J Pediatr Surg 2003; 38:430–433. 136.Widhalm K, Dietrich S, Prager G: Adjustable gastric banding surgery in morbidly obese adolescents: experience with 8 patients. Int J Obes Relat Metab Disord 2004;28(suppl 3):42S– 48S. 137.Silberhummer GR, Miller K, Kriwanek S, Widhalm K, Pump A, Prager G: laparoscopic adjustable gastric banding in adolescents: the Austrian experience. Obes Surg 2006;16:1062– 1067. 138.Capella JF, Capella RF: Bariatric surgery in adolescence: is this the best age to operate? Obes Surg 2003;13:826–832. 139.Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 10.1007/s11695-012- 0802-1. 140.Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab 2009; 35:518-23. 141.Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009; 250:234-41. 42 142.Hofso D, Nordstrand N, Johnson LK, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010; 163:735–745. 143.Schauer PR, Kashyap S, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese diabetic patients. N Engl J Med. 2012; 366:1567–1576. 144.Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012; 366:1577–1585. 145.Hofso D, Jenssen T, Bollerslev J, et al. Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2011; 164:231–238. 146.Hsu L., Benotti P., Dwyer J. Nonsurgical factors that influence the outcome of bariatric surgery: a review. Psychosom Med 1998; 60: 338-46 147.Fried M, Ribaric G, Buchwald JN, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/M2: an integrative review of early studies. Obes Surg 2010; 20: 776-790. 148.Lee WJ, Chong K, Chen CY, et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index < 35 kg/M2. Obes Surg 2011; 21: 889-895. 149.Demaria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database. Ann Surg 2010; 252: 559-566. 150.Lee WJ, Ser KH, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Surgery 2010; 147: 664- 669. 151.Buse JB, Caprio S, Cefalu WT et al: How do we define cure of diabetes? Diabetes Care 2009; 32, 11: 2133-2135. 152.Maggard-Gibbons M, Maglione M, Livhits M et al.: Bariatric Surgery for Weight Loss and Glycemic Control in Nonmorbidly Obese Adults With Diabetes. JAMA 2013; 309, 21:2250- 2261. 153.AACE/ACE Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan - 2015. Endocr Pract 2015; 21 (Suppl 1) 154.Dronge A., Percal H., Kancir S. et al. Long-term glycemic control and postoperative infectious complications. Arch Surg 2006; 141: 375-380 155.Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010; 95: 4823-43 156.Brolin R., Leung M. Survey of vitamin and mineral supplementation after gastric bypass and biliopancreatic diversion for morbid obesity. Obes Surg 1999; 9: 150-154 157.Skroubis G., Sakellapoulos G., Pouggouras K. et al. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes Surg 2002; 12: 551-558 158.Gasteyger C., Suter H., Gaillard R. et al. Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standart multivitamin supplementation. Am J Clin Nutr 2008; 87: 1128-33 159.Aasheim E., Hofso D., Hjelmesaeth J., Birkeland K., Bohmer T. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr 2008; 87:362-9 43